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Association between diabetes mellitus and
multi-drug-resistant tuberculosis: evidence
from a systematic review and meta-analysis
Balewgizie Sileshi Tegegne1,2, Melkamu Merid Mengesha1* , Andreas A. Teferra3, Mamaru Ayenew Awoke4
and Tesfa Dejenie Habtewold2
Abstract
Background: Diabetes mellitus (DM) poses a significant risk for the development of active tuberculosis (TB) and
complicates its treatment. However, there is inconclusive evidence on whether the TB-DM co-morbidity is associated
with a higher risk of developing multi-drug-resistant tuberculosis (MDR-TB). The aim of this meta-analysis was to
summarize available evidence on the association of DM and MDR-TB and to estimate a pooled effect measure.
Methods: PubMed, Excerpta Medica Database (EMBASE), Web of Science, World Health Organization (WHO), and
Global Health Library database were searched for all studies published in English until July 2018 and that reported the
association of DM and MDR-TB among TB patients. To assess study quality, we used the Newcastle-Ottawa Scale for
cohort and case-control studies and the Agency for Healthcare Research and Quality tool for cross-sectional studies.
We checked the between-study heterogeneity using the Cochrane Q chi-squared statistic and I2 and examined a
potential publication bias by visual inspection of the funnel plot and Egger’s regression test statistic. The random-effect
model was fitted to estimate the summary effects, odds ratios (ORs), and 95% confidence interval (CIs) across studies.
Results: This meta-analysis of 24 observational studies from 15 different countries revealed that DM has a significant
association with MDR-TB (OR = 1.97, 95% CI = 1.58–2.45, I2 = 38.2%, P value for heterogeneity = 0.031). The significant
positive association remained irrespective of country income level, type of DM, how TB or DM was diagnosed, and
design of primary studies. A stronger association was noted in a pooled estimate of studies which adjusted for at least
one confounding factor, OR = 2.43, 95% CI 1.90 to 3.12. There was no significant publication bias detected.
Conclusions: The results suggest that DM can significantly increase the odds of developing MDR-TB. Consequently, a
more robust TB treatment and follow-up might be necessary for patients with DM. Efforts to control DM can have a
substantial beneficial effect on TB outcomes, particularly in the case of MDR-TB.
Systematic review registration: PROSPERO CRD42016045692.
Keywords: Diabetes mellitus, Tuberculosis, Multi-drug-resistant tuberculosis, Systematic review, Meta-analysis
Background
The global tuberculosis (TB) burden continues to be a
major public health challenge despite efforts to reduce
its impact. Globally in 2016, there were an estimated
10.4 million incident cases of TB, equivalent to 140 cases
per 100, 000 population [1]. Of these incident cases of
TB in 2016, an estimated 1.9 million were attributed to
undernourishment, 1.0 million to HIV, 0.8 million to
smoking, and 0.8 million to diabetes [1]. In the era of
the sustainable development goals, post-2015, the “End
TB Strategy” targets to reduce TB incidence by 80% by
year 2030 [2]. However, the global epidemiological and
demographic transitions pose significant challenge to TB
control programs by changing the relative importance of
different risk factors for TB [3, 4].
The global diabetes mellitus (DM) epidemic poses a
significant bottleneck to the TB control program [3, 4].
The International Diabetes Federation (IDF) estimated
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that, globally in 2013, 382 million adults have diabetes of
whom 80% live in low-and middle-income countries.
Further increase in the global burden of diabetes is
predicted, reaching 592 million by 2035 [5]. People with
diabetes, compared to non-diabetic controls, were two-
to three-fold more likely to develop TB [6, 7]. In 2013,
an estimated 15% of adult cases of TB worldwide were
attributed to diabetes, which corresponds to 1 million
cases of diabetes-associated TB per year [3]. Impaired
immunity in diabetic patients is thought to contribute to
the evolution of latent TB infection to active cases.
Moreover, people with TB who have DM have a poorer
response to treatment than do those without DM, and
are therefore at a higher risk of TB treatment failure,
death, and relapse after cure [3, 8]. Treatment failure in
turn adds another significant challenge to the global TB
control program, a drug-resistant TB [1, 9].
Multi-drug-resistant tuberculosis (MDR-TB), resistance
to at least isoniazid and rifampicin, results from either pri-
mary infection with resistant bacteria or may develop in
the course of a patient’s treatment [9]. In 2016, there were
an estimated 600,000 incident cases of MDR-TB. In the
same year, an estimated 4.1% of new cases and 19% of pre-
viously treated TB cases had MDR-TB [1]. The emergence
of multi-drug resistance across the world poses a global
threat as the treatment is difficult, expensive, and a major
healthcare cost burden to developing countries [10]. Most
cases of MDR-TB arise from a mixture of physician error,
inadequate and incomplete treatment, and patient
non-compliance during treatment of susceptible TB [11,
12]. Research reports also indicate that patients with
MDR-TB and a co-morbidity of DM have a poor treat-
ment response compared with non-diabetic MDR-TB
controls [13].
The additional risk of DM for the development of
MDR-TB, however, remains controversial [14–16]. Many
previous studies have found a 2.1 to 8.8 times increased
risk of MDR-TB among TB patients co-morbid with dia-
betes [17–21]. In addition, observational studies from
Israel, Georgia, and Mexico showed that TB patients
with DM had a higher risk of developing MDR-TB [22–
24]. In contrast, several others reported that there is no
increased risk of MDR-TB among TB patients who have
DM [25–28]. Similarly, none but one of the previously
conducted systematic reviews and meta-analysis [29] re-
ported DM as an independent risk factor for MDR-TB.
However, the pooled estimate in that study was based on
limited number of studies which mostly implemented a
cross-sectional or case-control study design. By conduct-
ing a comprehensive search until July 2018, we identified
more studies and included six new cohort studies [30–
35]. Therefore, with the present systematic review and
meta-analysis, we aimed to assess the pooled effect esti-
mate of DM on the development of MDR-TB with the




Our systematic review has been registered with the
International Prospective Register of Systematic Reviews
(PROSPERO) (http://www.crd.york.ac.uk/prospero/dis-
play_record.asp?ID=CRD42016045692). The protocol
has been published elsewhere [36]. This review is written
in accordance with the recommendations from the Pre-
ferred Reporting Items for Systematic Review and
Meta-Analysis (PRISMA) statement guideline [37, 38],
and a completed PRISMA checklist has been included
(Additional file 1: Table S1).
Eligibility criteria
We included all observational studies (cross-sectional
cohort, case-control cohort, and prospective and retro-
spective cohorts) which reported the association of DM
and MDR-TB among TB patients. All eligible studies
published in English and prior to July 30, 2018, were in-
cluded for the review.
Data source and search strategy
PubMed, Excerpta Medica Database (EMBASE), Web of
Science, and WHO Global Health Library databases
were searched for all publications. We also searched
cross-references of identified articles. In consultation
with an experienced medical information specialist, a
comprehensive search strategy has been developed
(Table 1). Search results were compiled using citation
management software (RefWorks 2.0; ProQuest LLC,
Bethesda, MD, USA, http://www.refworks.com).
Study selection
Articles were screened and selected for full-text review if
they met the following selection criteria: (1) provided or
permitted the computation of an effect estimate of DM
on the development of MDR-TB; (2) included TB pa-
tients (all type) and defined MDR-TB based on standard
protocol; resistance at least to isoniazid and rifampicin
[9]; and (3) defined DM based on any of the following:
baseline diagnosis by self-report, medical records,
laboratory test, or treatment with oral hypoglycemic
medications or insulin. We excluded studies for any of
the following reasons: citations without abstracts,
anonymous reports, duplicate studies, case reports, or
studies which did not compare MDR-TB among people
with DM to people without DM, and systematic reviews
and meta-analysis. Additionally, studies that either did
not provide effect estimates in odds ratios, rate ratios,
hazard ratios, and relative risks or did not allow for the
computation of these values were excluded. Two authors
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(BS and MM) screened and checked full-text studies for
inclusion independently. Any disagreement was resolved
by discussion. If consensus could not be reached, a third
author determined the eligibility and approved the final
list of retained studies.
Quality assessment and data extraction
Meta-analysis of observational studies present particular
challenges because of potential biases in the original
studies and differences in study designs that make the
calculation of a single summary estimate of effect of ex-
posure potentially misleading [39]. Thus, assessing qual-
ity of studies using a standardized tool helps to classify
risk of bias which can help to explain variation in the re-
sults of included studies. Two authors (BS and MM)
checked the quality of studies independently using
Newcastle-Ottawa Scale (NOS) [40] for cohort and
case-control studies and the Agency for Healthcare Re-
search and Quality (AHRQ) [41] tool for cross-sectional
studies as shown in Additional file 2: Table S2.
Case-control and cohort studies qualified for inclusion if
they scored 7 points or more from a total of 9 points in
three domains of the equally weighted nine NOS com-
ponents: selection (4 points), comparability (2 points),
and exposure assessment (3 points). Cross-sectional
studies were included in the analysis if they fulfilled all
the four components (comparability, exposure, outcome
measurement, and statistical analysis) of the AHRQ cri-
teria. Structured data extraction form was constructed
and pre-tested. For every study that met our eligibility
criteria, two authors (BS and MM) independently ex-
tracted the title, name of authors, year of publication,
country, study design, study population, sample size,
data collection procedure, diagnosis of DM, and
MDR-TB. Crude or adjusted effect sizes (ORs) with
confidence intervals in the original studies were also
extracted.
Statistical analysis
We estimated pooled OR with their 95% CI to evaluate
the association between DM and MDR-TB among TB
patients. Potential sources of heterogeneity between the
studies were examined by using the Cochrane Q
chi-squared statistic and I2 [42, 43], where I2 > 75%
suggested considerable heterogeneity. Presuming the
variation of the true effect of DM on MDR-TB between
studies, the random-effect model [44] was fitted to esti-
mate the summary effect (ORs) and 95% CIs across
studies. Subgroup analyses were performed by study
type, variable adjustment, DM type, and TB type and by
the income level of the country where the primary study
was conducted. Publication bias was assessed with the
funnel plot for asymmetry, Egger’s test, and Begger’s
regression models [45]. To see the trend of evidence
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accumulation, we ran a cumulative meta-analysis. We
conducted an influence analysis to observe the effect of
omitting a single study on the overall pooled effect esti-
mate [46]. All analyses were performed using STATA SE
14.2 (Stata Corporation, College Station, TX) [47]. All
reported P values were two-sided at the level of 0.05.
Results
Search results
We identified a total of 1782 studies based on the litera-
ture search in four databases including PubMed (235),
EMBASE (525), Web of Science (254), and WHO Global
Health library (768). Additionally, we found nine studies
through a manual search (Fig. 1). After removal of dupli-
cate studies, 1112 articles were screened based on titles
and abstracts leaving 73 studies selected for a full-text
review. Furthermore, 16 records were excluded from the
full-text review (7 conference abstracts and correspond-
ence/short communications and 9 full texts not accessible
or available). Similarly, from the full-text review, we ex-
cluded 36 studies due to different reasons (6 were not
written in English, 10 did not include comparisons, 17 did
not define outcome clearly, and 3 had no enough outcome
to estimate risks). List of the excluded articles after
full-text review is available in Additional file 3. Finally, 21
articles were included for data synthesis. Additionally,
three articles [31, 48, 49] reported separate effect sizes for
newly diagnosed and previously treated TB patients, and
one study [50] reported separate effect estimate by
country (USA and Mexico), which resulted in a total of 25
studies or data points for analyses.
Study characteristics
Table 2 presents the characteristics of all the 25 studies
[14, 18–21, 23, 25, 28, 30–35, 48–54] with a total sample
of 13,403 participants with TB. The studies were
published between 2001 and 2018 and covered different
geographical regions: 13 studies were in Asia (three in
China, three in Taiwan, two in Georgia, one in
Bangladesh, one in Indonesia, one in Iran, one in
Thailand, and one in South Korea), three studies were in
Europe (one in Spain, one in Portugal, and one in Turkey),
eight studies were in the Americas (four in Mexico, two in
the USA, and two in Peru), and one study was in Africa
(Egypt). From the total studies included in the analysis,
nine were case-control [18–21, 23, 25, 32, 52, 54], eight
Fig. 1 Flow chart showing study selection process and search results
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were cohort [14, 30, 31, 33–35, 53], and eight were
cross-sectional [28, 48–51] by study design. No adjust-
ment for confounding was done in 12 of the included
studies, while the remaining studies adjusted for at least
one confounding factor. The most commonly adjusted
factors were age, sex, smoking status, and HIV status
(Table 2). All the included studies passed quality assessment
based on the Agency for Healthcare Research and Quality
(AHRQ) [41] tool for cross-sectional studies and
Newcastle-Ottawa Scale (NOS) [40] criteria for case-control
and cohort studies (Additional file 2: Table S2).
Associations between DM and MDR-TB
We explored the influence of each individual study on
the overall meta-analysis summary estimate. Table 3
shows the influence of omitting a single study on the
overall summary estimate. Accordingly, we identified
that omitting Magee MJ et al. [31] resulted in a large im-
provement on the overall summary estimate compared
to the combined summary estimate obtained by omitting
any one single study included in this meta-analysis
(Table 3). This study was then excluded from the rest of
the analysis resulting in 24 observational studies consi-
dered to conduct this meta-analysis.
Based on the meta-analysis of 24 observational studies,
the overall pooled effect estimate was 1.97 (OR = 1.97,
95% CI 1.58 to 2.45, I2 = 38.2%, P value for heterogeneity
= 0.031). This result indicated a 97% increased risk of
MDR-TB among TB-DM co-morbid patients. The signifi-
cant and positively increased risk of MDR-TB among
TB-DM co-morbid patients remained in the same direc-
tion in a subgroup analysis by study characteristics. When
seen by level of adjustment to a confounding factor,
studies which adjusted for at least one confounding
factor had more than a two-fold increased risk of
MDR-TB (OR = 2.43, 95% CI 1.90 to 3.12) (Fig. 2). In
a subgroup analysis of studies which adjusted for a
minimum of one confounding factor, a strong positive
association was observed by study design (cross-sec-
tional, 4 studies, OR = 1.72, 95% CI 1.23 to 2.41;
case-control, 5 studies, OR = 2.89, 95% CI 2.02 to
4.12; cohort, 4 studies, OR = 3.36, 95% CI 1.82 to
6.20) and method of TB diagnosis (culture confirmed,
8 studies, OR = 1.97, 95% CI 1.51 to 2.57; Sputum
smear test, 5 studies, OR = 3.73 95% CI 2.33 to 5.97)
(Table 4).
To evaluate consistency of the evidence over the years
along with its sufficiency, we ran a cumulative
meta-analysis which calculates effect estimates as newer
studies are added. Accordingly, between 2001 and 2014,
there was a positive association between DM and
MDR-TB but with a swinging effect size. However, with
the addition of three case-control and four cohort
studies between 2014 and 2018, a strong evidence that
TB patients co-morbid with DM had an increased risk
of developing MDR-TB has sustained (Fig. 3).
There was no significant publication bias found either by
the Egger’s regression asymmetry test or by a funnel plot
(Fig. 4a). The contour-enhanced funnel plot examination
(Fig. 4b) confirms this, which distinguished between publi-
cation bias and other causes. It showed that small studies
were found not only in the areas of statistical significance
but also in areas of non-statistical significance.
Discussion
In this study, we pooled estimates on the association
between DM and MDR-TB from 24 observational
studies and identified a significant and positive association
Table 3 Single study influence analysis on the overall meta-
analysis summary estimate of the association between diabetes
mellitus and multi-drug-resistant tuberculosis




Gomez-Gomez A et al. [23] 1.81 1.37 2.38
Magee MJ et al. [53] 1.82 1.38 2.40
Fisher-Hoch SP et al.† [50] 1.84 1.38 2.45
Hsu A et al.* [48] 1.85 1.40 2.44
Saktiawati AMI et al. [35] 1.75 1.36 2.26
Rifat M et al. [20] 1.80 1.36 2.38
Bashar M et al. [18] 1.76 1.35 2.29
Perez-Navarro LM et al. [30] 1.77 1.35 2.33
Fisher-Hoch SP et al. [50] 1.82 1.38 2.41
Perez-Navarro LM et al. [19] 1.80 1.37 2.35
Salindri AD et al. [33] 1.81 1.38 2.38
Min J et al. [52] 1.81 1.37 2.38
Hsu A et al. [48] 1.88 1.43 2.46
Chang JT [14] 1.83 1.38 2.42
Zhang Q et al. [51] 1.82 1.37 2.43
Hafez S et al. [32] 1.81 1.38 2.38
Magee MJ et al.* [31] 1.88 1.43 2.48
Jitmuang A et al. [54] 1.86 1.41 2.46
Mi F et al.* [49] 1.93 1.49 2.49
Suarez-Garcia I et al. [21] 1.83 1.40 2.41
Magee MJ et al. [31] 1.97 1.58 2.45
Baghaei P et al. [25] 1.88 1.44 2.46
Tanrikulu A et al. [28] 1.79 1.37 2.35
Mi F et al. [49] 1.87 1.41 2.46
Carreira S et al. [34] 1.84 1.40 2.41
Combined 1.83 1.40 2.39
UCL upper confidence limit, LCL lower confidence limit, CI confidence interval,
OR odds ratio
*These studies reported separate effect sizes for newly diagnosed and
previously treated tuberculosis patients
†This study reported separate effect sizes by country (USA and Mexico)
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with a low between-study heterogeneity. In a pooled
estimate of studies which adjusted for at least one con-
founding factor, stronger association was observed by
study design, type of TB, method of TB diagnosis, type of
DM, method of DM diagnosis, and country income level.
The pooled effect estimate, in subgroup analyses of
13 studies which adjusted for at least one confound-
ing factor, on the association between DM and
MDR-TB (OR = 2.43, 95% CI 1.90 to 3.12, I2 = 19.1%,
P value = 0.250) was consistent in the direction of as-
sociation, but stronger than what was reported in a
previous systematic review and meta-analysis (OR =
1.71, 95% CI 1.32 to 2.22, I2 = 46.8%, P value = 0.020)
[29]. This difference could be due to the fact that Liu
et al. [29] mixed three studies which reported un-
adjusted OR [21, 49, 54], while we included three
new cohort studies that reported adjusted OR [30, 33,
35]. Compared to a similar prior meta-analysis [29],
we included 10 additional studies [14, 25, 28, 30–35,
51] and supplemented this with strong analytical
rigor. Thus, our meta-analysis fortifies the evidence
base for the association between DM and MDR-TB.
Our results are also in agreement with a review that
showed TB and DM co-morbidity were more likely to
be evident among people with anti-TB drug resistance
[55], signifying a clear association between the two
diseases. In another review, Baker et al. [8] did not
find an increased risk of MDR-TB among people with
DM. However, it is worth mentioning that this study
aimed to review literature on the impact of DM on
TB outcomes, and this particular sub-analysis in-
cluded only four studies. Although not having
MDR-TB as an outcome, another review noted signifi-
cant associations in the pooled risk of association
NOTE: Weights are from random effects analysis
.
.
Overall  (I-squared = 38.2%, p = 0.031)
Suarez-Garcia I et al.(2009)
Hsu A et al.(2012)
Gomez-Gomez A et al.(2015)
Subtotal  (I-squared = 19.1%, p = 0.250)
Carreira S et al.(2012)
Magee MJ et al.(2013)
Fisher-Hoch SP et al.(2008)
Magee MJ et al.(2015)
Saktiawati AMI et.al(2018)
Chang JT(2011)
Tanrikulu A et al.(2008)
Mi F et al.(2014)
Baghaei P et al.(2009)
Fisher-Hoch SP et al.(2008)
Subtotal  (I-squared = 35.4%, p = 0.115)
Mi F et al.(2014)
Zhang Q et al.(2009)
AuthorYr
Min J et al.(2005)
Perez-Navarro LM et al.(2017)
No adjustment
Bashar M et al.(2001)
Jitmuang A et al.(2015)
Perez-Navarro LM et al.(2015)
Hsu A et al.(2012)
Hafez S et al.(2013)
Rifat M et al.(2014)
Adjusted at least for one factor
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Odds Ratio
Fig. 2 Forest plot showing the results of random effects meta-analysis of 24 observational studies. The horizontal line and vertical dotted line in
the middle indicate the 95% confidence interval and its corresponding odds ratio (OR) estimate
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between DM and active TB without regarding the
type of study design implemented [56].
Signifying a stability of association, we found a signifi-
cant and positive association between DM and MDR-TB
in subgroup analyses of studies which adjusted for at
least one confounding factor. The association persisted
irrespective of the country where the primary studies
were conducted which covered diverse population
groups, how DM or TB diagnosis was made, and study
design of the primary studies. However, pooled estimate
of a weaker strength was found in studies which did not
adjust for at least one confounding factor (OR = 1.45,
95% CI 1.05 to 2.02). We included studies which
reported unadjusted effect estimate to reduce inflation
of the pooled effect estimate from the adjusted only ana-
lysis, increase the number of available studies for ana-
lysis, and widen the representativeness of our findings
[57]. Although unadjusted findings lack adjustment by
statistical methods, they attempted to adjust at the
design level albeit still suffering from an unobserved
confounding effect. Therefore, we suggest our findings
should be interpreted with caution.
In subgroup analyses of studies which adjusted for at
least one confounding factor on the association between
DM and MDR-TB, there was an increased risk in lower
middle-income countries (OR = 2.95, 95% CI 1.69 to
5.16) compared to that found in upper middle-income
countries (OR = 2.32, 95% CI 1.65 to 3.28) and
high-income countries (OR = 2.13, 95% CI 1.29 to 3.52).
This might be due to more studies in high-income- or
upper middle-income country settings diagnosed DM by
blood test (FBS or HbA1c) or confirmed TB diagnosis
based on culture which may have reduced bias due to mis-
classification [19, 23, 30, 48, 50, 52]. Consistent with our
Table 4 Subgroup analyses of 24 observational studies on the association between diabetes mellitus and multi-drug-resistant-
tuberculosis among tuberculosis patients co-morbid with diabetes mellitus
Study characteristics Studies that adjusted for at least one covariate Studies that did not adjustment for covariates
No. of studies Pooled OR (95% CI) I2 (%) P value¥ No. of studies Pooled OR (95% CI) I2 (%) P value¥
Study design
Case control 5 2.89 (2.02, 4.12) 0.0 0.773 4 1.39 (0.79, 2.45) 0.0 0.459
Cohort 4 3.36 (1.82, 6.20) 40.2 0.171 3 1.47 (0.93, 2.34) 0.0 0.501
Cross sectional 4 1.72 (1.23, 2,41) 19.1 0.250 4 1.45 (0.68, 3.09) 73.2 0.011
Type of TB
Both or not defined 7 2.72 (1.88, 3.94) 38.4 0.136 7 1.90 (1.40, 2.60) 0.0 0.492
New 5 2.36 (1.59, 3.51) 3.8 0.385 2 1.64 (0.99, 2.71) 0.0 0.436
Previously treated 1† 2 0.77 (0.36, 1.67) 35.4 0.115
Diagnosis of TB
Culture confirmed 8 1.97 (1.51, 2.57) 0.0 0.831 8 1.60 (1.08, 2.38) 43.6 0.088
Sputum smear test only 5 3.73 (2.33, 5.97) 28.0 0.235 3 1.03 (0.58, 182) 0.0 0.736
Type of DM
Type 2 6 2.67 (1.82, 3.93) 40.7 0.134 3 1.12 (0.52, 2.42) 67.3 0.047
Type 1 and type 2 5 2.22 (1.31, 3.76) 35.8 0.183 3 1.77 (1.08, 2.89) 35.5 0.212
Not defined 2 2.37 (1.29, 4.34) 0.0 0.872 5 1.46 (0.84, 2.51) 0.0 0.428
Diagnosis of DM
HbA1c or FBS 3 2.42 (1.49, 3.93) 0.0 0.981 1†
Only FBS 6 2.68 (1.45, 4.96) 53.5 0.056 6 1.50 (0.93, 2.42) 51.6 0.066
Self-report/unspecified 4 2.33 (1.65, 3.29) 21.5 0.282 4 1.49 (0.77, 2.89) 21.9 0.279
Country income level*
Lower middle income 4 2.95 (1.69, 5.16) 40.6 0.168 1†
Upper middle income 4 2.32 (1.65, 3.28) 0.0 0.418 7 1.27 (0.80, 2.01) 56.9 0.031
High income 5 2.13 (1.29, 3.52) 34.6 0.191 3 1.88 (1.07, 3.29) 0.0 0.963
Overall 13 2.43 (1.90, 3.12) 19.1 0.250 11 1.45 (1.05, 2.02) 35.4 0.115
OR odds ratio, I2 the variation in estimate attributable to heterogeneity, ¥ P value for heterogeneity, CI confidence interval, TB tuberculosis, DM diabetes mellitus,
FBS fasting blood sugar, HbA1c glycosylated hemoglobin
†Effect estimate not pooled due limited number of available studies
*Income level based on World Bank Classification (https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups)
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finding that there was an increased risk of MDR-TB among
TB-DM co-morbid patients in lower middle-income
countries, a meta-analysis by Al-Rifai et al. [56] reported
that there was a higher risk of TB-DM association in lower
middle-income countries compared to high-and upper
middle-income countries.
A strong association was found in subgroup analyses
by TB type in studies which reported adjusted estimate,
where DM increased the risk of MDR-TB among new
TB patients (OR = 2.36, 95% CI 1.59 to 3.51) and in
those with undefined TB type (OR = 2.72, 95% CI 1.88 to
3.94). However, due to inadequate number of studies
which adjusted for at least one confounding factor and
included only previously treated TB patients, we did not
present a pooled estimate on the risk of MDR-TB among
previously treated TB-DM co-morbid patients. There-
fore, we are not able to confirm whether DM is indeed
not a risk factor for MDR-TB among previously treated
TB patients. The meta-analysis by Liu et al. [29] also re-
ported similar findings on the risk of any MDR-TB (OR
= 1.94, 95% CI 1.42 to 2.65) and primary MDR-TB (OR
= 1.69, 95% CI 1.09 to 2.62) among TB patients
co-morbid with DM. Due to the addition of three cohort
studies [30, 33, 35], which were not included in the Liu
et al.’s meta-analysis [29], we reported a stronger pooled
effect estimate for the increase in the risk of MDR-TB
among new- and any-TB patients co-morbid with DM.
Similarly, irrespective of the study design used in the
primary studies which adjusted for at least one con-
founding factor, we consistently found a significant and
positive association between DM and MDR-TB in
cross-sectional (OR = 1.72 95% CI 1.23 to 2.41),
case-control (OR = 2.89, 95% 2.02 to 4.12), and cohort
studies (OR = 3.36, 95% CI 1.82, 6.20). Similar findings
were reported by Liu et al. for case-control studies but
not for cross-sectional studies [29]. Because only one
Bashar M et al.(2001)
Min J et al.(2005)
Fisher-Hoch SP et al.(2008)
Fisher-Hoch SP et al.(2008)
Tanrikulu A et al.(2008)
Suarez-Garcia I et al.(2009)
Zhang Q et al.(2009)
Baghaei P et al.(2009)
Chang JT(2011)
Hsu A et al.(2012)
Carreira S et al.(2012)
Hsu A et al.(2012)
Magee MJ et al.(2013)
Hafez S et al.(2013)
Rifat M et al.(2014)
Mi F et al.(2014)
Mi F et al.(2014)
Perez-Navarro LM et al.(2015)
Jitmuang A et al.(2015)
Gomez-Gomez A et al.(2015)
Magee MJ et al.(2015)
Salindri AD et al.(2016)





















































Reducerisk of MDR-TB  Increase risk of MDR-TB 
1.1 5 10 15
Odds Ratio
Fig. 3 Cumulative forest plot showing the results of random effects meta-analysis for the 24 observational studies on the association of DM and
MDR-TB. The first row shows the effect based on one study, the second row shows the cumulative effect based on two studies, and so on
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cohort study was included [53] by Liu et al. [29], we
cannot compare the pooled estimate from cohort studies
in our meta-analysis to theirs. Though it is difficult to
establish causality based on evidence from observational
studies, we believe that these pooled estimates from
studies which controlled for potential confounding fac-
tors further solidify the existence of a strong association
between DM and MDR-TB among patients co-morbid
with TB.
In this study, we have shown the most substantial evi-
dence to date on the association between DM and
MDR-TB by including a comprehensive list of studies
carried out in various settings around the world. Me-
thodologically, we conducted a cumulative meta-analysis
to see the trend of evidence and performed a single
study influence analysis and subgroup analysis. However,
we would also like to acknowledge potential limitations
of this study. Firstly, we have not included studies
published in non-English languages. Given majority of
MDR-TB cases and co-morbidities are from Russia,
China, and India [1], exclusion of studies from these
countries might bias our finding. Secondly, the inclusion
of studies which did not consistently define the type of
TB and did not control for potential confounding factors
increased the observed heterogeneity among studies.
However, in an attempt to deal with this, we have
performed and reported sensitivity analysis. Finally, po-
tential misclassification regarding a non-uniform diagno-
sis of DM and TB among participants included in the
different studies might have contributed to varying risk
estimates. This is particularly observed in the stratified
analysis based on diagnosis of DM and TB, where higher
estimates were observed for those diagnosed based on
information obtained from medical records and self-
reports, (diagnosis of DM: FBS from medical record,
OR = 2.68, 95% CI 1.45 to 4.96; HbA1c, OR = 2.42, 95%
CI 1.49 to 3.93; self-report, OR = 2.33,, 95% CI 1.65 to
3.29) and (diagnosis of TB: culture confirmed, OR =
1.97, 95% CI 1.51 o 2.57; AFB only from medical record,
OR = 3.73, 95% CI 2.33 to 5.97).
In conclusion, our results demonstrate that a more ro-
bust TB treatment and follow-up might be necessary for
patients with DM. In light of the global DM epidemic
[5], this study emphasizes the message that there is a
strong need for a bi-directional screening and
co-management approach in the attempt to halt the
TB-DM co-morbidity [58]. Even though countries repre-
senting diverse income levels were not included in our
study, we stress the need to maximize efforts to prevent
DM and TB co-morbidity and reduce the burden of
MDR-TB in countries with varying economical stan-
dings. The integrated and collaborative effort between
TB and DM control programs will ultimately count
on achieving the global “End TB Strategy” [2]. Efforts
to control DM can have a substantial beneficial effect
on TB outcomes, particularly in the case of MDR-TB.
Policymakers can focus on new targets pertaining to
an enhanced care plan for DM patients with TB, par-
ticularly among the slightest evidence of problems
with adherence or prolonged and complicated infec-
tions. Furthermore, focus on the early identification
and treatment of individuals with the co-morbidity
can result in an enhanced treatment outcome. We
recommend future prospective cohort studies to focus
on bacteriologically confirmed TB cases that object-
ively diagnose DM, with clearly defined types of both
TB and DM coupled with robust controls for poten-
tial confounding.
a b
Fig. 4 Funnel plot a and contour-enhanced funnel plot b of the included observational studies. In the contour-enhanced plot, the shaded region
indicates areas of statistical significance, and non-statistical significance is represented in white. The vertical line corresponds to the summary log
(OR) as estimated from the random-effect model (OR, odds ratio)
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